公司資料
Grifols 股價、新聞與催化劑
- 股票代碼:
- GRFS
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
7.40 USD (0.00%)
收盤價
最後更新: 2026年9月17日
5.19B USD
市值
股價為何變動
截至 2026年9月17日，GRFS 股價變化不大，收於 $7.40。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Grifols is a plasma-therapeutics company with a major business in immunoglobulins, plasma-derived medicines, and diagnostics.
所在地與產業分類
Headquartered in Spain and listed in the United States as an ADR, Grifols has a global plasma and diagnostics footprint.
商業模式特徵
The company depends on plasma collection, manufacturing execution, and steady demand for specialty biologics.
生技產業定位
Grifols sits in a unique biologics niche where supply chain, pricing, and plasma collection trends matter as much as clinical catalysts.
未來催化劑
- Grifols’ catalysts are plasma-collection recovery, debt-reduction execution, and any step that makes the balance-sheet story less distracting. This matters because it helps show whether the company can turn its current footprint into a cleaner earnings profile. Better execution here can matter even before a new product or trial headline lands.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。